Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from COSMO Pharmaceuticals N.V. ( (CH:COPN) ).
Cosmo Pharmaceuticals N.V. has received CE certification for its ColonPRO EU, an advanced AI software platform for colonoscopy, marking a significant milestone in its expansion into the European market. This certification, following FDA approval in the U.S., underscores Cosmo’s leadership in AI-assisted endoscopy and its commitment to innovation in colorectal cancer prevention, enhancing the company’s market position and offering improved care standards for patients.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF77.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
More about COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a life-science company focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing. The company designs, develops, and manufactures advanced solutions to meet critical medical needs and improve the standard of care, with technologies trusted by leading global pharma and MedTech companies.
YTD Price Performance: 9.77%
Average Trading Volume: 19,915
Technical Sentiment Signal: Buy
Current Market Cap: CHF1.14B
For an in-depth examination of COPN stock, go to TipRanks’ Overview page.